within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AE01_Ofloxacin;

model Ofloxacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.98,
    Cl = 3.888888888888889e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.12,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018500000000000003,
    Tlag = 10.200000000000001,
    Vdp = 0.052,
    k12 = 6.11111111111111e-06,
    k21 = 6.11111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ofloxacin</td></tr><tr><td>ATC code:</td><td>S01AE01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>120</td><td>L</td></tr>
    <tr><td>clearance:</td><td>14</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ofloxacin is a broad-spectrum fluoroquinolone antibiotic used to treat a variety of bacterial infections, including respiratory tract infections, urinary tract infections, skin infections, and eye infections. It inhibits bacterial DNA gyrase and topoisomerase IV. Ofloxacin is approved for use worldwide and remains a commonly used antibiotic both systemically and as an ophthalmic agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for ofloxacin in healthy adult subjects following a single oral dose.</p><h4>References</h4><ol><li><p>Jaruratanasirikul, S, et al., &amp; Samaeng, M (2018). Population Pharmacokinetics and Pharmacodynamics Modeling of Oral Levofloxacin. <i>Journal of the Medical Association of Thailand = Chotmaihet thangphaet</i> 99(8) 886–892. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29947489/\">https://pubmed.ncbi.nlm.nih.gov/29947489</a></p></li><li><p>Stambaugh, JJ, et al., &amp; Peloquin, CA (2002). Ofloxacin population pharmacokinetics in patients with tuberculosis. <i>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</i> 6(6) 503–509. DOI:<a href=\"https://doi.org/10.5588/09640569513011\">10.5588/09640569513011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12068983/\">https://pubmed.ncbi.nlm.nih.gov/12068983</a></p></li><li><p>Zhang, J, et al., &amp; Zhang, YY (2009). Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China. <i>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</i> 15(5) 293–300. DOI:<a href=\"https://doi.org/10.1007/s10156-009-0714-8\">10.1007/s10156-009-0714-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19856067/\">https://pubmed.ncbi.nlm.nih.gov/19856067</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01AE01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ofloxacin;
